Kenneth Wilson
Psychiatry · Poughkeepsie, NYNPI 1780747220
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,572 of the $9,942 with a category attached, or 66.1%. 24 manufacturers reported payments, led by Johnson & Johnson at 38.4% of the total. Reporting peaked in 2020 at $3,699 and has fallen 59.8% since, to $1,486 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $44.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$790
- Axsome Therapeutics, Inc.$597
- Teva Pharmaceuticals USA, Inc.$571
- Neurocrine Biosciences, Inc.$568
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$3,30033%
- Food & beverage$6,57266%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 40 | $3,822 |
| AbbVie(2 entities) | 63 | $1,205 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $790 |
| Axsome Therapeutics, Inc. | 12 | $597 |
| Teva Pharmaceuticals USA, Inc. | 17 | $571 |
| Neurocrine Biosciences, Inc. | 9 | $568 |
| Alkermes, Inc. | 11 | $534 |
| Otsuka America Pharmaceutical, Inc. | 13 | $486 |
| E.r. Squibb & Sons, L.L.C. | 6 | $325 |
| Sunovion Pharmaceuticals Inc. | 2 | $209 |
| Lundbeck LLC | 9 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $168 |
| Eisai Inc. | 1 | $98 |
| Avanir Pharmaceuticals, Inc. | 3 | $56 |
| Bausch Health US, LLC | 3 | $55 |
| Ironshore Pharmaceuticals Inc. | 3 | $50 |
| Corium, LLC | 2 | $47 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Alfasigma USA, Inc. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Biogen | 1 | $26 |
| Vertical Pharmaceuticals, LLC | 1 | $23 |
| Shire North American Group Inc | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,942 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 25 | $61,947 |
| Aripiprazole | 28 | $3,162 |
| Clozapine | 12 | $2,014 |
| Bupropion XlBupropion Hcl | 57 | $1,396 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 52 | $1,390 |
| Fluphenazine Hcl | 12 | $1,327 |
| Risperidone | 33 | $1,006 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $920 |
| Oxcarbazepine | 16 | $803 |
| Clonazepam | 106 | $589 |
| Quetiapine Fumarate | 44 | $584 |
| Trazodone Hcl | 49 | $499 |
| Escitalopram Oxalate | 49 | $496 |
| Lamotrigine | 48 | $477 |
| Fluoxetine Hcl | 32 | $294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $486 | $61,94725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Poughkeepsie
- Kishor ZinzuvadiaPoughkeepsie$488K
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.